MSDI is now on the run. Monster Digital shareholders has a schedule vote for merging with Innovate bio, they're releasing a clinical phase III trial study for Celiac Disease, the only treatment for the disease is a gluten free diet. Innovate has the only trial study drug treatment of Celiac disease. I'm in @ .605 and adding. Don't miss out on the .60's this is going to run hard before the merger.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.